secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K/A
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001213900-25-040194
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma regains Nasdaq compliance after equity shortfall notice
----------------------------------------------------------------------

- On April 30, 2025, Nasdaq notified ABVC that stockholders' equity of $723,959 as of April 23 failed Listing Rule 5550(b)(1).
- On May 5, 2025, Nasdaq confirmed compliance after ABVC's Q1 2025 10-Q showed equity of $7,956,295, closing the matter.
- The company avoided delisting by demonstrating equity above the required minimum through its quarterly filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390025040194/0001213900-25-040194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390025040194/ea0240961-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-040194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer